OM:EKTA BMedical Equipment
Elekta (OM:EKTA B) Valuation Check After FDA Clearance For Evo CT Linac Entry Into US Market
Elekta (OM:EKTA B) has attracted fresh attention after its Elekta Evo CT-Linac received FDA 510(k) clearance, opening the door for U.S. adoption of its AI supported imaging and radiation therapy platform.
See our latest analysis for Elekta.
The FDA clearance arrives at a time when Elekta’s share price has a 90 day share price return of 20.20% and a 30 day share price return of 6.47%, while the 1 year total shareholder return of a 2.89% decline and 5 year total shareholder return of a 40%...